AzTrials
AzTrials

Dental Pulp NecrosisNCT01814436

Revitalization of Immature Permanent Teeth With Necrotic Pulps Using SHED Cells

A study testing scaffold-free SHED-derived pellet in people with Dental Pulp Necrosis and Permanent Incisor Avulsed by Trauma, run by Air Force Military Medical University, China at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Revitalization of Young Immature Permanent Teeth With Necrotic Pulps Using Autologous Stem Cells from Human Exfoliated Deciduous Teeth Read more about this study

Who is it for?
Ages 7 to 12 years
What is being tested?
scaffold-free SHED-derived pellet
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteChina
Study dates
Feb 2013to Oct 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 to 12 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Those who has signed the informed consent.
  • Those who are between 7-years-old to 12-years-old.
  • Those with at least one young permanent teeth with pulp necrosis which caused by trauma or permanent incisor avulsed by trauma.
  • Those who can provide the health deciduous teeth.
  • Those who have accomplished initial preparation and have been showing good compliance.
  • Those whose guardians understand the purposes of the trial and are capable of making an independent decision to comply with trial requirements
  • Those who are able to visit our hospital in accordance with the trial schedule

Who cannot join

  • Those in an extremely poor nutritional condition (serum albumin concentration <2 g/dL)
  • Those whose guardians would not cooperate with the treatment.
  • Those who has uncontrollable oral disease.
  • Those with severe dental fear.
  • Those with coexisting mental or consciousness disorder.
  • Those with teeth dysplasia and/or hereditary disease history.
Show all 16Show fewer
  • Those with systemic disease which may affect the postoperative healing.
  • Those with bruxism and malocclusion.
  • Loss of the avulsed teeth.
  • Those who are taking the medicine which would affect the postoperative healing.
  • Those with the bad oral habits.
  • Those who are undertaking other trail meanwhile or few weeks ago.
  • Those coexisting disease of the blood or immune system.
  • Those who are not capable to provide the deciduous dental pulp cells.
  • Those with the severe tooth trauma (crown-root or root fracture, tooth displacement).
  • Others who the investigators or sub-investigators determined as unsuitable for the trial.

Trial locations and contacts

1 site in 1 country.

China1 site, 1 recruiting
  • School of Stomatology, Fourth Military Medical University

    Xi'an, Shaanxi, 710032

    Yan Jin, PhD, 86-29-84776147, yanjinfmmu@gmail.com

    yan Jin, PhD

    Recruiting

Other trials in China

About this study

Official title: Revitalization of Young Immature Permanent Teeth With Necrotic Pulps Using Autologous Stem Cells From Human Exfoliated Deciduous Teeth

Revitalization of Young Immature Permanent Teeth With Necrotic Pulps Using Autologous Stem Cells from Human Exfoliated Deciduous Teeth

Read the detailed description

Irreversible damage to immature permanent teeth as a result of noxious infection or local trauma before normal physiological closure of the apical structure represents a real clinical challenge. The conventional therapeutic approach is to consider the use of synthetic biocompatible materials, such as calcium hydroxide [Ca(OH)2] and mineral trioxide aggregate (MTA), to induce apical closure, or apexification, by forming a hard tissue barrier across the root apex. However, neither MTA nor calcium hydroxide are currently able either to induce or stimulate pulp regeneration, or to ensure that conventional root development continues once damage has taken place, so that the inherent risk of root fracture remains.

Millions of teeth are accidentally avulsed each year due to the serious trauma in sports, motor vehicle accidents, criminal assaults, and fist fights, among other incidents. The risk is higher in children while their permanent teeth are still immature which may led to lots of complications and also more challenges in treatment. Generally, tooth reimplantation is the most effective therapy for tooth avulsion, As we know, The success of tooth reimplantation depends on the maintenance of vitality of the periodontal ligament, which need the parents and teachers act quickly (e.g., within 2 h) and that the avulsed tooth should preserved in an appropriate medium, such as milk or physiological saline, because the viable cells in the remaining periodontal ligament (PDL) on the root surface play a crucial role in recovering the avulsed tooth functions.

Along with the development of new regenerative protocols to resolve clinical deficiencies, continuing advances in the discovery and characterization of stem cells of dental origin-able to differentiate into multiple tissue types-have recently broadened possible therapeutic horizons towards pulp and periodontal tissue regeneration. Some studies have suggested that the recent discovery and characterization of stem cells from human exfoliated deciduous teeth (SHED) form the cell source of apexogenesis in immature teeth with periradicular periodontitis of endodontic origin. The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.

This is a single-centre, randomized, controlled study. This study has been approved by the ethical committees of School of Stomatology, Fourth Military Medical University. The study will be conducted according to the Declaration of Helsinki.

Being tested
scaffold-free SHED-derived pellet
Medical subject headings
Dental Pulp Necrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • scaffold-free SHED-derived pelletDevice

    Also called SHED pellet

    The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with avulsed immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.

Study groups in NCT01814436
Study groupRoleWhat they receive
scaffold-free SHED-derived pelletExperimentalNot described
Receives: Device: scaffold-free SHED-derived pellet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pulp and Apical regeneration

    The main outcome measures in the study protocol were: pulp status evaluated by dental pulp vitality tester; pulp revascularization examined by laser dopler flow meter, and the index of clinical examination. In addition, we examined whether and to what extent adverse events, for which causal relationships with the use of SHED cell was not ruled out, emerged.

    The other main outcome measures in the study protocol were: the degree of apical closure; the rate of increase in root length and the change of root canal wall thickness. We examined and evaluate the anatomic morphology of teeth roots using dental computer tomography. We set rate of increase in root length as the most statistically important outcome (primary outcome).

    Measured: 1 year following transplantation

Secondary outcomes (1)
  1. Clinical parameters

    periapical lesion and tooth mobility

    Measured: 3~12 month following transplantation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Mar 2013 (estimated)
  2. Study startFeb 2013
  3. Primary completionJul 2017 (estimated)
  4. Study completionOct 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01814436
Sponsor's protocol ID
FourthMMU2013
Status last verified
Apr 2016
First submitted
16 Mar 2013
Last updated
28 Apr 2016
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing scaffold-free SHED-derived pellet in people with Dental Pulp Necrosis and Permanent Incisor Avulsed by Trauma, run by Air Force Military Medical University, China at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Apr 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact kun xuan (86-29-84776087, xuankun@fmmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pulp and Apical regeneration (time frame: 1 year following transplantation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2016; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in